Medicine, Hematology Oncology Division

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Kehinde Adekola

Kehinde Adekola

Person: Academic

20122018
No photo of Mark Agulnik

Mark Agulnik

Person: Academic

20012023
No photo of Jessica K Altman

Jessica K Altman

Person: Academic

20052021

Research Output 1956 2019

Inhibitors of Tumor Angiogenesis

Shah, AN. & Gradishar, WJ., 2019, Cancer Chemotherapy, Immunotherapy, and Biotherapy: Principles and Practice, 6th edition. Chabner, B. & Longo, DL. (eds.). Philadelphia: Wolters Kluwer

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Quantitative method to track proteolytic invasion in 3D collagen

Ebine, K., Chow, C. R. & Munshi, H. G., Jan 1 2019, Methods in Molecular Biology. Humana Press Inc, p. 161-169 9 p. (Methods in Molecular Biology; vol. 1882).

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Collagen
Neoplasms
Gels

6mer seed toxicity in tumor suppressive microRNAs

Gao, Q. Q., Putzbach, W. E., Murmann, A. E., Chen, S., Sarshad, A. A., Peter, J. M., Bartom, E. T., Hafner, M. & Peter, M. E., Dec 1 2018, In : Nature communications. 9, 1, 4504.

Research output: Contribution to journal › Article

MicroRNAs
toxicity
Toxicity
Seed
Tumors

Grants 1995 2027

Prot #Pevonedistat-1015: A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients with Advanced Solid Tumors

Mahalingam, D.

PRA Health Sciences, Millennium Pharmaceuticals, Inc

11/28/18 → 11/28/21

Project: Research project

Prot #BST002: A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy

Frankfurt, O.

PRA Health Sciences, BioSight Ltd.

10/29/18 → 10/29/21

Project: Research project

Prot #MK3475-716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

Chandra, S.

DrugDev Inc., Merck Sharp & Dohme Corp.

10/25/18 → 10/25/21

Project: Research project